5. Conclusion
We demonstrated in our cohort that low EVI1 expression at diagnosis
predicted poor outcomes in pediatric Ph-negative BCP-ALL patients
receiving chemotherapy only, which was validated by TARGET ALL Expansion
(Phase 2) project cohort. It implied the necessity to test EVI1
transcript at diagnosis for stratification. The current result needs to
be confirmed in other cohort and the prognostic impact of EVI1
expression in BCP-ALL patients receiving allogeneic stem cell
transplantation remains to be evaluated. Furthermore, prospective
multicenter trial is warranted, and the mechanism of the effect need be
investigated.